Vyant Bio (VYNT) Stock Price, News & Analysis

Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Key Stats

• Today's Range: $0.18 to $0.20
• 50-Day Range: $0.19 to $0.19
• 52-Week Range: $0.14 to $1.58
• Volume: 19,100 shs
• Average Volume: 161,822 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VYNT Stock Analysis - Frequently Asked Questions

How have VYNT shares performed this year?

Vyant Bio's stock was trading at $0.1940 at the start of the year. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940.
View the best growth stocks for 2024 here.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (OTCMKTS:VYNT) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). The business earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%.

When did Vyant Bio's stock split?

Vyant Bio shares reverse split before market open on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vyant Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 12/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:VYNT
• CUSIP: N/A
• CIK: 1349929
• Web: stemonix.com
• Phone: (201) 479-1357
• Fax: 201-528-9201
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,690,000.00
• Net Margins: -3,474.81%
• Pretax Margin: -3,281.86%
• Return on Equity: -151.82%
• Return on Assets: -97.14%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 2.86
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: $670,000.00
• Price / Sales: 1.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.69 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 6,330,000
• Free Float: 5,724,000
• Market Cap: $1.23 million
• Optionable: Not Optionable
• Beta: 1.73